2214. National Testing Assessment of Select Bacterial STIs During the COVID-19 Pandemic
Fonseca G, Maier M, Keddem S, Borgerding J, Lowy E, McFarland L, Comstock E, Van Epps P, Ohl M, Hauser R, Ross D, Beste L. 2214. National Testing Assessment of Select Bacterial STIs During the COVID-19 Pandemic. Open Forum Infectious Diseases 2022, 9: ofac492.1833. DOI: 10.1093/ofid/ofac492.1833.Peer-Reviewed Original ResearchTesting ratesSyphilis testsCOVID-19 pandemicGC testingVeterans Health Administration healthcare systemCT/GCNumber of ChlamydiaOverall testing rateElectronic health record dataAge 25 yearsHealth record dataSTI testing ratesNear-baseline levelsSelf-reported raceBackground ChlamydiaSTI diagnosisSyphilis infectionBacterial STIsSTI testingHIV statusInfection testingPatient groupRetrospective studySyphilis testingPre-pandemic levelsScreening for Latent Infections Among Users of High-Risk Immunosuppressants: A Cross-Sectional Analysis From the Veterans Health Administration Healthcare System
Schmajuk G, Montgomery A, Tarasovsky G, Li J, Hauser R, Rozenberg-Ben-Dror K, Whooley M. Screening for Latent Infections Among Users of High-Risk Immunosuppressants: A Cross-Sectional Analysis From the Veterans Health Administration Healthcare System. Journal Of Patient Safety 2022, 19: 1-7. PMID: 36395779, DOI: 10.1097/pts.0000000000001079.Peer-Reviewed Original ResearchConceptsHigher screening ratesVeterans Health AdministrationScreening ratesCross-sectional analysisHepatitis B virusHepatitis C virusLatent hepatitis B virusVeterans Affairs (VA) Corporate Data WarehouseElectronic health record-based toolsVeterans Health Administration healthcare systemNational Veterans Health AdministrationCross-sectional analysis of veteransLow-performing facilitiesGuideline-recommended screeningFacility-level factorsB/ts-DMARDsMixed-effects multivariable logistic regression modelAnalysis of veteransCorporate Data WarehouseMultivariate logistic regression modelHigher-volume facilitiesBlack/African American patientsLogistic regression modelsSynthetic disease-modifying antirheumatic drugsTargeted synthetic disease-modifying antirheumatic drugs